Scancell Holdings PLC · LSE:SCLP
Scancell — Shareholder Meeting (October 2015)
20 slides from Scancell's shareholder meeting presentation, Oct 20, 2015

Slide 1: Innovation in Immuno-Oncology
INNOVATION in IMMUNO-‐ONCOLOGY AGM Presenta,on: October 20th 2015 Dr Richard Goodfellow: Co-‐CEO, Scancell Holdings plc Prof Lindy Durrant: Co-‐CEO, Scancell Holdings plc 1

Slide 2: Company Profile
COMPANY PROFILE Translating innovative science into ground-‐breaking new products Ø Focus on cancer immunotherapy Ø Two cu>ng edge pla?orm technologies – ImmunoBody® and Moditope® Ø Outstanding clinical efficacy and safety on lead product SCIB1 for paHents with stage III/IV resected metastaHc mela

Slide 3: Value Drivers
VALUE DRIVERS Ultra high T cell avidity delivers outstanding efIicacy and safety Ø SCIB1 combined with checkpoint inhibitors for late stage disease and as monotherapy in adjuvant melanoma Ø ExcepHonal survival and safety in resected stage III/IV paHents Ø Checkpoint inhibitors only have 25-‐30%

Slide 4: Future Plans
FUTURE PLANS A Road Map for the future Ø A phase 2 controlled randomised clinical trial to confirm efficacy of SCIB1 in combinaHon with checkpoint inhibitors Ø A phase 3 adjuvant melanoma study Ø Phase 1/2 clinical trial with Modi-‐1 in breast and ovarian cancer Ø Strengthen Board and management c

Slide 5: SCIB1-001 Study Design Used for Phase 1/2 Trial
SCIB1-‐001 STUDY DESIGN USED FOR PHASE 1/2 TRIAL PART 1 – Dose escalation in patients with stage III/IV melanoma (with or without tumour) Ø Primary ObjecHve – safety and tolerability Ø Secondary ObjecHves – immune responses; tumour responses Dose escalaHon with safety assessment a_er 3 doses (0.4

Slide 6: SCIB1 Clinical Trial – Highlights
SCIB1 CLINICAL TRIAL – HIGHLIGHTS Ø All 20 paHents with resected tumours at study entry remain alive Ø Two paHents with tumour present at study entry have shown a reducHon in tumour size or complete destrucHon of tumours Patient'04*16' Patient'04*28' !(i)!Pre(treatment !(ii)!9!months! !(i)!Pre(tre

Slide 7: Survival of All Resected Patients
SURVIVAL OF ALL RESECTED PATIENTS Ø 16 paHents received 2-‐4 mg doses of SCIB1 Ø All remain alive Ø 31% have progressed Ø Median observaHon Hme = 39 months from study entry Ø Compares favourably with other studies Ø Five conHnue to receive further doses of SCIB1 SCIB1%median%follow%up%at%%39%

Slide 8: Summary of SCIB1
SUMMARY OF SCIB1 Ø Scancell’s ImmunoBody® pla?orm, in combinaHon with electroporaHon, sHmulates potent T cell responses Ø SCIB1 shrinks and even destroys tumours in paHents with inoperable metastaHc melanoma Ø SCIB1 prevents disease recurrence and prolongs overall survival in paHents with fully r

Slide 9: Moditope
MODITOPE® Ø Moditope® is a new and proprietary pla?orm for acHvaHng the immune system against tumour cells Ø Moditope® exploits the normal immune response to stressed cells, which is largely mediated by cytotoxic CD4+ T cells Ø When normal cells are stressed or dying, they start to digest their o

Slide 10: Moditope Progress Update – Components of First Candidate Modi-1 Identified
MODITOPE® PROGRESS UPDATE – 1 Components of Iirst Moditope® development candidate, Modi-‐1, identiIied Ø First target was vimenHn – a major cytoskeletal protein, with two citrullinated vimenHn pepHdes selected for inclusion in Modi-‐1 Ø AddiHonal enolase pepHde idenHfied, inclusion of which signi

Slide 11: Moditope Progress Update – Modi-1 Potentially Effective in Up to 95% of Population
MODITOPE® PROGRESS UPDATE – 2 Modi-‐1 has the potential to be effective in up to 95% of the population Ø Previous studies indicated that only paHents with a parHcular haplotype, HLA-‐DR4, would respond to vimenHn and enolase pepHdes (approximately 25% of populaHon) Ø Scancell has now shown that

Slide 12: Moditope Progress Update – First Biologically Relevant Animal Model
MODITOPE® PROGRESS UPDATE – 3 Scancell has developed the world’s Iirst biologically relevant animal model for the detection of CD4 T cell responses Ø Most tumours do not express MHC-‐II unless it is induced by inflammaHon and are therefore not targets for CD4 T cells Ø Gamma interferon-‐inducible

Slide 13: Moditope Conclusions
MODITOPE® CONCLUSIONS Ø Moditope® pla?orm exemplified by lead product Mod-‐1 Ø Modi-‐1 pepHde components increased to extend tumour coverage and paHent eligibility Ø OpHmised Modi-‐1 now suitable for treatment of up to 95% of paHents rather than 25% (due to HLA restricHon) Ø Inclusion of Eno-

Slide 14: Clinical Development Plans
CLINICAL DEVELOPMENT PLANS Ø SCIB1 + checkpoint inhibitor combinaHon phase 2 study Ø SCIB1 adjuvant phase 3 study Ø Modi-‐1 phase 1/2 clinical study 14

Slide 15: SCIB1 + Checkpoint Inhibitor Combination
SCIB1 + CHECKPOINT INHIBITOR COMBINATION RATIONALE Ø Checkpoint inhibitors targeHng PD-‐1 have yielded impressive results in the treatment of paHents with metastaHc melanoma Ø Despite this success, response rates have not exceeded 25-‐30% Ø A majority of paHents may not respond to PD-‐1 inhibi

Slide 16: SCIB1 Synergy in Combination with Anti-PD.1
SCIB1 SYNERGY IN COMBINATION WITH ANTI-‐PD.1 Ø Immunised with SCIB1, murine-‐specific anH-‐PD.1 anHbody or both SCIB1 + anH-‐PD.1 Ø SCIB1 provides equivalent survival compared to inhibiHng PD.1 Ø Combining anH-‐PD.1 therapy with SCIB1 significantly enhances survival, resulHng in 85% survival o

Slide 17: Our Vision for Future Immunotherapy of Melanoma
OUR VISION FOR FUTURE IMMUNOTHERAPY OF MELANOMA Stage * Incidence 5 year Therapy (%) survival (%) 1A 97 Surgery 67 IB 92 Surgery IIA 81 Surgery, SCIB1 IIB 19 70 Surgery, SCIB1 IIC 53 Surgery, SCIB1 IIIA** 78 Surgery, SCIB1 IIIB 11 59 Surgery, SCIB1, checkpoint inhibitors, BRAF inhibitors IIIC 40 Sur

Slide 18: SCIB1 Adjuvant Phase 3 Study
SCIB1 ADJUVANT PHASE 3 STUDY TARGET INDICATION: Adjuvant therapy in melanoma patients with fully-‐resected disease Ø Treatment of paHents a_er surgical removal of tumours Ø Therapy targeted at metastaHc disease which rapidly leads to disease recurrence Ra,onale Ø Currently over 360,000 paHents i

Slide 19: Phase 1/2 Study of Modi-1 in Patients with Advanced Malignancy
PHASE 1/2 STUDY OF MODI-‐1 IN PATIENTS WITH ADVANCED MALIGNANCY Ø A first-‐in-‐human phase 1/2 study of Modi-‐1 in paHents with advanced malignancy for whom no standard therapy is considered appropriate, or for whom standard therapy is considered intolerable Ø Phase 1 will assess the safety and

Slide 20: Potential Synergy Between ImmunoBody and Moditope
POTENTIAL SYNERGY BETWEEN IMMUNOBODY® AND MODITOPE® ImmunoBody® Moditope® High avidity CD8+ T cell responses Potent CD4+ T cell responses DNA product PepHde product Eradicates small primary and Eradicates large bulky tumours metastaHc tumours Checkpoint inhibitors may enhance No requirement for chec
Source: Internet Archive copy of scancell.co.uk
More decks from Scancell Holdings PLC
Investor Presentation (August 2026)35 slides · August 2026
Investor Presentation (July 2026)35 slides · July 2026
H1 FY2026 Earnings Presentation18 slides · Jan 29, 2026
Technical Presentation (December 2025)25 slides · Dec 11, 2025
ESMO Immuno-Oncology Congress 202525 slides · Dec 10, 2025
Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting 202516 slides · November 2025